Essential roles of IGFBP-3 and IGFBP-rP1 in breast cancer

Angelika M Burger1, Brian Leyland-Jones, Kris Banerjee

  • 1Laboratory of Molecular Pathology, Department of Anatomic Pathology and Division of Molecular and Cellular Biology, Sunnybrook and Women's College Health Sciences Centre, Toronto, Ont., Canada. angelikaburger@aol.com

European Journal of Cancer (Oxford, England : 1990)
|June 28, 2005
PubMed

Insights

Insulin-like growth factor binding proteins (IGFBPs), specifically IGFBP-3 and IGFBP-rP1, play distinct roles in breast cancer. Their unique binding affinities for IGFs and insulin suggest potential in cancer risk assessment and treatment development.

Area of Science:

  • Endocrinology
  • Molecular Biology
  • Oncology

Background:

  • Insulin and insulin-like growth factors (IGFs) are crucial for growth regulation but become dysregulated in cancer.
  • The insulin-like growth factor binding protein (IGFBP) superfamily comprises 16 members with diverse functions.
  • IGFBP-3 and IGFBP-rP1 exhibit unique ligand-binding properties within this superfamily.

Purpose of the Study:

  • To review the roles of IGFBP-3 and IGFBP-rP1 in breast cancer.
  • To explore the potential of these proteins in assessing breast cancer risk.
  • To discuss their implications for developing novel breast cancer therapies.

Main Methods:

  • Literature review of studies on IGFBP-3 and IGFBP-rP1 in breast cancer.
  • Analysis of ligand-binding affinities and biological functions.
  • Synthesis of information regarding their involvement in mammary carcinoma.

Main Results:

  • IGFBP-3 binds IGFs with high affinity, transporting most serum IGFs, and has low affinity for insulin.
  • IGFBP-rP1 binds insulin with high affinity, distinguishing it from other IGFBPs, while having low affinity for IGFs.
  • Both proteins are implicated in the complex signaling pathways of breast cancer.

Conclusions:

  • IGFBP-3 and IGFBP-rP1 possess distinct molecular characteristics relevant to breast cancer.
  • Their unique binding profiles offer potential as biomarkers for breast cancer risk stratification.
  • Targeting IGFBP-3 and IGFBP-rP1 may represent a promising therapeutic strategy for breast cancer treatment.

Related Concept Videos

Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Regulation of the Unfolded Protein Response01:31

Regulation of the Unfolded Protein Response

Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal01:22

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.